This is therefore a contrasting of the analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership in Amicus Therapeutics Inc. (NASDAQ:FOLD) and Apellis Pharmaceuticals Inc. (NASDAQ:APLS). The two are both Biotechnology companies that compete with one another.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Amicus Therapeutics Inc.||108.59M||27.01||419.38M||-1.89||0.00|
|Apellis Pharmaceuticals Inc.||N/A||0.00||156.34M||-2.05||0.00|
We can see in table 1 the earnings per share, top-line revenue and valuation of Amicus Therapeutics Inc. and Apellis Pharmaceuticals Inc.
Table 2 provides the return on assets, return on equity and net margins of the two firms.
|Net Margins||Return on Equity||Return on Assets|
|Amicus Therapeutics Inc.||-386.20%||-63.4%||-37%|
|Apellis Pharmaceuticals Inc.||0.00%||-48.3%||-39.9%|
9.1 and 9 are the respective Current Ratio and a Quick Ratio of Amicus Therapeutics Inc. Its rival Apellis Pharmaceuticals Inc.’s Current and Quick Ratios are 14.9 and 14.9 respectively. Apellis Pharmaceuticals Inc. has a better chance of clearing its pay short and long-term debts than Amicus Therapeutics Inc.
Ratings and Recommendations for Amicus Therapeutics Inc. and Apellis Pharmaceuticals Inc. can be find in next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Amicus Therapeutics Inc.||0||0||3||3.00|
|Apellis Pharmaceuticals Inc.||0||0||1||3.00|
Amicus Therapeutics Inc. has a consensus price target of $19, and a 49.25% upside potential. Meanwhile, Apellis Pharmaceuticals Inc.’s consensus price target is $45, while its potential upside is 135.85%. Based on the results delivered earlier, Apellis Pharmaceuticals Inc. is looking more favorable than Amicus Therapeutics Inc., analysts view.
Institutional and Insider Ownership
Institutional investors owned 0% of Amicus Therapeutics Inc. shares and 59.3% of Apellis Pharmaceuticals Inc. shares. Insiders owned 1% of Amicus Therapeutics Inc. shares. Competitively, insiders own roughly 20.7% of Apellis Pharmaceuticals Inc.’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Amicus Therapeutics Inc.||11.74%||15.45%||29.42%||3.73%||-2.11%||45.09%|
|Apellis Pharmaceuticals Inc.||23.33%||31.79%||16.7%||-2.95%||-0.43%||39.88%|
For the past year Amicus Therapeutics Inc. has stronger performance than Apellis Pharmaceuticals Inc.
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its principal product is the migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which has completed two global Phase III registration studies. The company is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; and AT3375 to treat Parkinson’s disease. It is conducting a Phase 1/2 clinical study of ATB200-02 to investigate pompe treatment paradigm in pompe patients. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidates include APL-2 and APL-1, to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy, intermediate age-related macular degeneration, and chronic obstructive pulmonary disease. The company develops APL-2 for subcutaneous injection, which is an injection into the tissue under the skin, and for intravitreal injection that is an injection into the eye, as well as APL-1 for inhaled administration. Apellis Pharmaceuticals, Inc. was founded in 2009 and is based in Crestwood, Kentucky.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.